JP2010521442A - 局所製剤処方 - Google Patents
局所製剤処方 Download PDFInfo
- Publication number
- JP2010521442A JP2010521442A JP2009553196A JP2009553196A JP2010521442A JP 2010521442 A JP2010521442 A JP 2010521442A JP 2009553196 A JP2009553196 A JP 2009553196A JP 2009553196 A JP2009553196 A JP 2009553196A JP 2010521442 A JP2010521442 A JP 2010521442A
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- diclofenac
- nsaid
- polyhydric alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012049 topical pharmaceutical composition Substances 0.000 title description 6
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims abstract description 63
- 239000000203 mixture Substances 0.000 claims abstract description 63
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229960001259 diclofenac Drugs 0.000 claims abstract description 22
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 22
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 22
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims abstract description 19
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 18
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 15
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims abstract description 9
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims abstract description 9
- -1 fatty acid ester Chemical class 0.000 claims abstract description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 5
- 239000000194 fatty acid Substances 0.000 claims abstract description 5
- 229930195729 fatty acid Natural products 0.000 claims abstract description 5
- 239000000725 suspension Substances 0.000 claims abstract description 4
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims abstract description 3
- 239000012071 phase Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 150000002632 lipids Chemical class 0.000 claims description 13
- 230000000699 topical effect Effects 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 150000002576 ketones Chemical class 0.000 claims description 5
- 230000002821 anti-nucleating effect Effects 0.000 claims description 4
- 230000036407 pain Effects 0.000 claims description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229940044949 eucalyptus oil Drugs 0.000 claims description 3
- 239000010642 eucalyptus oil Substances 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 3
- 229940041616 menthol Drugs 0.000 claims description 3
- 230000001953 sensory effect Effects 0.000 claims description 3
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 2
- 238000011200 topical administration Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 231100000245 skin permeability Toxicity 0.000 description 10
- 239000000499 gel Substances 0.000 description 8
- 230000004907 flux Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000006184 cosolvent Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical group CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 4
- 229960000991 ketoprofen Drugs 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 3
- 229960001193 diclofenac sodium Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000001839 systemic circulation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229960005466 diclofenac diethylammonium Drugs 0.000 description 2
- 150000002085 enols Chemical group 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
- 229960004752 ketorolac Drugs 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000010587 phase diagram Methods 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000019448 polyvinylpyrrolidone-vinyl acetate copolymer Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- MILWSGRFEGYSGM-UHFFFAOYSA-N propane-1,2-diol;propane-1,2,3-triol Chemical compound CC(O)CO.OCC(O)CO MILWSGRFEGYSGM-UHFFFAOYSA-N 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0704846.5A GB0704846D0 (en) | 2007-03-13 | 2007-03-13 | Topical pharmaceutical formulation |
| PCT/GB2008/000540 WO2008110741A2 (en) | 2007-03-13 | 2008-02-15 | Topical pharmaceutical formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010521442A true JP2010521442A (ja) | 2010-06-24 |
| JP2010521442A5 JP2010521442A5 (enExample) | 2011-04-14 |
Family
ID=37988913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009553196A Pending JP2010521442A (ja) | 2007-03-13 | 2008-02-15 | 局所製剤処方 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8541470B2 (enExample) |
| EP (2) | EP2131813B1 (enExample) |
| JP (1) | JP2010521442A (enExample) |
| CN (1) | CN101663022A (enExample) |
| AU (1) | AU2008224735B2 (enExample) |
| BR (1) | BRPI0808887A2 (enExample) |
| CA (1) | CA2680074C (enExample) |
| CO (1) | CO6220926A2 (enExample) |
| DK (1) | DK2131813T3 (enExample) |
| ES (1) | ES2391914T3 (enExample) |
| GB (1) | GB0704846D0 (enExample) |
| MX (1) | MX2009009758A (enExample) |
| MY (1) | MY149545A (enExample) |
| NZ (1) | NZ579895A (enExample) |
| PL (1) | PL2131813T3 (enExample) |
| PT (1) | PT2131813E (enExample) |
| RU (1) | RU2468794C2 (enExample) |
| SG (1) | SG179480A1 (enExample) |
| TW (1) | TWI367110B (enExample) |
| UA (1) | UA100509C2 (enExample) |
| WO (1) | WO2008110741A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018505905A (ja) * | 2015-02-20 | 2018-03-01 | フューチュラ メディカル ディベロップメンツ リミテッドＦｕｔｕｒａ Ｍｅｄｉｃａｌ Ｄｅｖｅｌｏｐｍｅｎｔｓ Ｌｉｍｉｔｅｄ | 局所医薬製剤 |
| JP2020514342A (ja) * | 2017-03-07 | 2020-05-21 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド | 活性化合物のための局所送達系 |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1687019T1 (en) * | 2003-11-20 | 2018-04-30 | Novo Nordisk A/S | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
| CN105175433A (zh) | 2008-10-17 | 2015-12-23 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| PH12012500726A1 (en) | 2009-10-14 | 2019-07-10 | Xenon Pharmaceuticals Inc | Synthetic methods for spiro-oxindole compounds |
| RU2596488C2 (ru) | 2010-02-26 | 2016-09-10 | Ксенон Фармасьютикалз Инк. | Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
| US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| CA2869547A1 (en) | 2012-04-12 | 2013-10-17 | Xenon Pharmaceuticals Inc. | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
| CN104968330A (zh) * | 2013-01-14 | 2015-10-07 | 因佛斯特医疗有限公司 | 用于治疗剧痛的组合物及方法 |
| WO2014108574A1 (en) * | 2013-01-14 | 2014-07-17 | Biocopea Limited | Solid solution compositions and use in severe pain |
| WO2014117999A1 (en) * | 2013-02-04 | 2014-08-07 | Biocopea Limited | Compositions and methods for treating chronic inflammation and inflammatory diseases |
| US9012402B1 (en) * | 2014-06-11 | 2015-04-21 | James Blanchard | Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation |
| US10596117B1 (en) | 2014-12-31 | 2020-03-24 | Eric Morrison | Lipoleosomes as carriers for aromatic amide anesthetic compounds |
| US10561627B2 (en) | 2014-12-31 | 2020-02-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films |
| US11007161B1 (en) | 2014-12-31 | 2021-05-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films |
| US9682033B2 (en) | 2015-02-05 | 2017-06-20 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
| FR3041534B1 (fr) * | 2015-09-30 | 2019-03-15 | Vetoquinol Sa | Composition de nettoyant auriculaire |
| GB201609968D0 (en) * | 2016-06-07 | 2016-07-20 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
| WO2017218920A1 (en) | 2016-06-16 | 2017-12-21 | Teva Pharmaceuticals International Gmbh | Asymmetric synthesis of funapide |
| US10821075B1 (en) | 2017-07-12 | 2020-11-03 | James Blanchard | Compositions for topical application of a medicaments onto a mammalian body surface |
| RS65380B1 (sr) | 2017-08-24 | 2024-04-30 | Novo Nordisk As | Glp-1 kompozicije i njihova upotreba |
| CN115135304A (zh) | 2020-02-18 | 2022-09-30 | 诺和诺德股份有限公司 | Glp-1组合物及其用途 |
| GB2596286B (en) | 2020-06-20 | 2023-01-25 | Francis Davis Adrian | Adherence to topical therapy |
| GB2597526A (en) | 2020-07-27 | 2022-02-02 | Incanthera R&D Ltd | Topical formulation |
| US20230270735A1 (en) | 2020-07-27 | 2023-08-31 | Incanthera (R&D) Ltd | Topical formulation |
| GB202012836D0 (en) | 2020-08-17 | 2020-09-30 | Futura Medical Developments Ltd | Topical composition |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62263122A (ja) * | 1986-05-07 | 1987-11-16 | Taro Ogiso | 経皮吸収剤 |
| WO2001060336A1 (en) * | 2000-02-14 | 2001-08-23 | The Procter & Gamble Company | Compositions for topical delivery of a pharmaceutically active agent having reduced skin irritation |
| WO2004017998A2 (en) * | 2002-08-22 | 2004-03-04 | Novartis Consumer Health S.A. | Topical emulsion- gel composition comprising diclofenac sodium |
| WO2005027977A2 (en) * | 2003-09-22 | 2005-03-31 | Agis Industries (1983) Ltd. | Diclofenac compositions for the treatment of skin disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10019171A1 (de) * | 2000-04-07 | 2001-10-18 | Schering Ag | Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe |
| US7132452B2 (en) * | 2003-03-10 | 2006-11-07 | Fang-Yu Lee | Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection |
| EP1588697A1 (en) | 2004-04-16 | 2005-10-26 | Kurt H. Prof. Dr. Bauer | Emulsion gel for topical application of pharmaceuticals |
| US20050244522A1 (en) * | 2004-04-30 | 2005-11-03 | Carrara Dario Norberto R | Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents |
-
2007
- 2007-03-13 GB GBGB0704846.5A patent/GB0704846D0/en not_active Ceased
-
2008
- 2008-02-15 ES ES08709428T patent/ES2391914T3/es active Active
- 2008-02-15 WO PCT/GB2008/000540 patent/WO2008110741A2/en not_active Ceased
- 2008-02-15 MX MX2009009758A patent/MX2009009758A/es active IP Right Grant
- 2008-02-15 DK DK08709428.0T patent/DK2131813T3/da active
- 2008-02-15 CN CN200880007936A patent/CN101663022A/zh active Pending
- 2008-02-15 MY MYPI20093774A patent/MY149545A/en unknown
- 2008-02-15 US US12/530,960 patent/US8541470B2/en active Active
- 2008-02-15 SG SG2012017497A patent/SG179480A1/en unknown
- 2008-02-15 EP EP08709428A patent/EP2131813B1/en not_active Not-in-force
- 2008-02-15 EP EP12154983A patent/EP2452671A2/en not_active Withdrawn
- 2008-02-15 NZ NZ579895A patent/NZ579895A/en not_active IP Right Cessation
- 2008-02-15 CA CA2680074A patent/CA2680074C/en active Active
- 2008-02-15 RU RU2009136228/15A patent/RU2468794C2/ru active
- 2008-02-15 PT PT08709428T patent/PT2131813E/pt unknown
- 2008-02-15 AU AU2008224735A patent/AU2008224735B2/en not_active Ceased
- 2008-02-15 PL PL08709428T patent/PL2131813T3/pl unknown
- 2008-02-15 JP JP2009553196A patent/JP2010521442A/ja active Pending
- 2008-02-15 BR BRPI0808887-0A patent/BRPI0808887A2/pt not_active Application Discontinuation
- 2008-02-15 UA UAA200910111A patent/UA100509C2/ru unknown
- 2008-02-20 TW TW097105840A patent/TWI367110B/zh not_active IP Right Cessation
-
2009
- 2009-10-08 CO CO09111579A patent/CO6220926A2/es not_active Application Discontinuation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62263122A (ja) * | 1986-05-07 | 1987-11-16 | Taro Ogiso | 経皮吸収剤 |
| WO2001060336A1 (en) * | 2000-02-14 | 2001-08-23 | The Procter & Gamble Company | Compositions for topical delivery of a pharmaceutically active agent having reduced skin irritation |
| WO2004017998A2 (en) * | 2002-08-22 | 2004-03-04 | Novartis Consumer Health S.A. | Topical emulsion- gel composition comprising diclofenac sodium |
| WO2005027977A2 (en) * | 2003-09-22 | 2005-03-31 | Agis Industries (1983) Ltd. | Diclofenac compositions for the treatment of skin disorders |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018505905A (ja) * | 2015-02-20 | 2018-03-01 | フューチュラ メディカル ディベロップメンツ リミテッドＦｕｔｕｒａ Ｍｅｄｉｃａｌ Ｄｅｖｅｌｏｐｍｅｎｔｓ Ｌｉｍｉｔｅｄ | 局所医薬製剤 |
| JP2020514342A (ja) * | 2017-03-07 | 2020-05-21 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド | 活性化合物のための局所送達系 |
| JP7250689B2 (ja) | 2017-03-07 | 2023-04-03 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド | 活性化合物のための局所送達系 |
Also Published As
| Publication number | Publication date |
|---|---|
| UA100509C2 (ru) | 2013-01-10 |
| US20100099767A1 (en) | 2010-04-22 |
| AU2008224735B2 (en) | 2013-04-18 |
| SG179480A1 (en) | 2012-04-27 |
| PL2131813T3 (pl) | 2012-11-30 |
| EP2452671A2 (en) | 2012-05-16 |
| GB0704846D0 (en) | 2007-04-18 |
| DK2131813T3 (da) | 2012-10-29 |
| MY149545A (en) | 2013-09-13 |
| RU2468794C2 (ru) | 2012-12-10 |
| PT2131813E (pt) | 2012-10-31 |
| MX2009009758A (es) | 2009-09-24 |
| CO6220926A2 (es) | 2010-11-19 |
| AU2008224735A1 (en) | 2008-09-18 |
| TWI367110B (en) | 2012-07-01 |
| CA2680074A1 (en) | 2008-09-18 |
| CN101663022A (zh) | 2010-03-03 |
| CA2680074C (en) | 2016-07-12 |
| BRPI0808887A2 (pt) | 2014-09-02 |
| RU2009136228A (ru) | 2011-04-20 |
| EP2131813B1 (en) | 2012-08-08 |
| ES2391914T3 (es) | 2012-12-03 |
| EP2131813A2 (en) | 2009-12-16 |
| WO2008110741A3 (en) | 2009-03-12 |
| WO2008110741A2 (en) | 2008-09-18 |
| WO2008110741A8 (en) | 2009-11-19 |
| TW200836769A (en) | 2008-09-16 |
| US8541470B2 (en) | 2013-09-24 |
| NZ579895A (en) | 2012-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010521442A (ja) | 局所製剤処方 | |
| US20050158348A1 (en) | Vehicle for topical delivery of anti-inflammatory compounds | |
| JP4549006B2 (ja) | ゲル軟膏 | |
| CN106572970B (zh) | 用于局部给药非甾体抗炎药以缓解肌肉骨骼疼痛的新型凝胶及其制备方法 | |
| JP5052558B2 (ja) | ゲル軟膏 | |
| MX2011008095A (es) | La administracion transdermica del diclofenaco, la carbamazepina y la bencidamina. | |
| JPH02191214A (ja) | 医薬活性剤の経皮デリバリー用組成物 | |
| US10028927B2 (en) | Topical pharmaceutical formulation | |
| JP7150308B2 (ja) | 皮膚外用組成物 | |
| ES2533854T3 (es) | Composiciones farmacéuticas transdérmicas que comprenden danazol | |
| JP2012092067A (ja) | 非ステロイド性消炎鎮痛外用剤 | |
| JP2024507011A (ja) | エマルション組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および／または処置におけるその使用 | |
| JP2004131472A (ja) | 痔疾治療用軟膏 | |
| CA2500907A1 (en) | Vehicle for topical delivery of anti-inflammatory compounds | |
| US11376213B2 (en) | Topical pharmaceutical formulation | |
| HK1140954A (zh) | 局部药物制剂 | |
| ES2758198T3 (es) | Composiciones analgésicas pulverizables | |
| JP2004099486A (ja) | フリーラジカル性疾患用外用剤 | |
| HK1170676A (en) | Topical pharmaceutical formulation | |
| JP2005089345A (ja) | 虫刺され治療薬 | |
| JPH0276816A (ja) | 外用剤 | |
| TR2024002454A1 (tr) | Topical compositions comprising nimesulide and diclofenac sodium and a salicylate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110208 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130312 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130531 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130625 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131119 |